2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 Wiley 2026暑期线上学习营 | 报名正式开启！ | 热 多本ABS四星！优质经管国际期刊列表 | 热 全流程投稿协助套餐服务 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Cancer Communications CANCER COMMUN （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.0
56人评分
我要评分
声誉 8.1 影响力 6.1 速度 6.8 | |||||||||||||||||||||
| 期刊ISSN | 2523-3548 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：28.48 | |||||||||||||||||||||
| 2025-2026自引率 | 0.7%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 31.399数据由网友[crystalmaple18]收集提供 | |||||||||||||||||||||
| h-index | 暂无h-index数据 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://onlinelibrary.wiley.com/journal/25233548 | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/cac2 | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study Author: Hao, Xuezhi; Wang, Lin; Hao, Yanrong; Hu, Yanping; Chen, Chun; Chen, Bi; Huang, Yunchao; Zang, Aimin; Wang, Yan; Chen, Zhendong; Zhuang, Wu; Shi, Jinsheng; Ren, Xiubao; Nie, Ligong; Yu, Guohua; Luo, Feng; Mao, Yimin; Wang, Xiang; Li, Baolan; Bai, Yuansong; Shi, Jianhua; Ni, Hongyan; Hou, Xiaoli; Yu, Haoyu; Li, Jing; Wang, Qingyu; Zhu, Jun; Shi, Yuankai Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0034 Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation Author: Zhang, Hui; Gu, Leirong; Su, Xiameng; Chen, Wanjin; Tan, Ming; Yu, Haibo; Zhou, Hongzhong; Gao, Tingting; Wang, Zhiling; Chen, Xinyan; Chen, Weixian; Chen, Juan; Cheng, Shengtao Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0028 Targeting Grade-Specific Endoplasmic Reticulum Stress Vulnerabilities in Chondrosarcoma: Divergent Roles of Protein Kinase R-Like Endoplasmic Reticulum Kinase and Inositol-Requiring Enzyme 1α Signaling Author: Chen, Hongtai; Su, Zezhuo; Lam, Ying Lee; Yau, Raymond Ching Hin; Leung, Anderson Siu Ming; Leung, Gabriel Ching Ngai; Honiball, John Robert; Oreffo, Richard O. C.; Cheung, Jason Pui Yin; Choi, Siu Wai; Cheung, Kelvin Sin Chi Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0026 Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study Author: Li, Haifeng; Chen, Meiting; Huang, Riqing; Rong, Qixiang; Hao, Jing; Zheng, Qiufan; Su, Yanhong; Shu, Ditian; Zhang, Yue; Yang, Wei; Lei, Xuefen; Cai, Yuchen; Xue, Cong; An, Xin; Shi, Yanxia Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0025 | |||||||||||||||||||||
| 期刊语言要求 | Language Manuscripts must be written in American English and be grammatically and linguistically correct. Authors should seek assistance with style, grammar and vocabulary if necessary. Your manuscript may also be sent back to you for revision if the quality of English language is poor. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Cancer Communications的语言要求，还能让Cancer Communications编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Cancer Communications编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2800; GBP2100; EUR2400; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：clinical trials、epidemiology、cellular biology、cancer、molecular biology、genetics 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774 | |||||||||||||||||||||
| 出版商 | Wiley | |||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Cancer Research | |||||||||||||||||||||
| 出版国家或地区 | PEOPLES R CHINA | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2018 | |||||||||||||||||||||
| 年文章数 | 49点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 98.61% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 73.47% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) 中科院的全球OA期刊索引（OAJ） | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2523-3548%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 4 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD2800; GBP2100; EUR2400; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Cancer Communications顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study Author: Hao, Xuezhi; Wang, Lin; Hao, Yanrong; Hu, Yanping; Chen, Chun; Chen, Bi; Huang, Yunchao; Zang, Aimin; Wang, Yan; Chen, Zhendong; Zhuang, Wu; Shi, Jinsheng; Ren, Xiubao; Nie, Ligong; Yu, Guohua; Luo, Feng; Mao, Yimin; Wang, Xiang; Li, Baolan; Bai, Yuansong; Shi, Jianhua; Ni, Hongyan; Hou, Xiaoli; Yu, Haoyu; Li, Jing; Wang, Qingyu; Zhu, Jun; Shi, Yuankai Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0034 PubMed DOI |
| 2. | Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation Author: Zhang, Hui; Gu, Leirong; Su, Xiameng; Chen, Wanjin; Tan, Ming; Yu, Haibo; Zhou, Hongzhong; Gao, Tingting; Wang, Zhiling; Chen, Xinyan; Chen, Weixian; Chen, Juan; Cheng, Shengtao Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0028 PubMed DOI |
| 3. | Targeting Grade-Specific Endoplasmic Reticulum Stress Vulnerabilities in Chondrosarcoma: Divergent Roles of Protein Kinase R-Like Endoplasmic Reticulum Kinase and Inositol-Requiring Enzyme 1α Signaling Author: Chen, Hongtai; Su, Zezhuo; Lam, Ying Lee; Yau, Raymond Ching Hin; Leung, Anderson Siu Ming; Leung, Gabriel Ching Ngai; Honiball, John Robert; Oreffo, Richard O. C.; Cheung, Jason Pui Yin; Choi, Siu Wai; Cheung, Kelvin Sin Chi Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0026 PubMed DOI |
| 4. | Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study Author: Li, Haifeng; Chen, Meiting; Huang, Riqing; Rong, Qixiang; Hao, Jing; Zheng, Qiufan; Su, Yanhong; Shu, Ditian; Zhang, Yue; Yang, Wei; Lei, Xuefen; Cai, Yuchen; Xue, Cong; An, Xin; Shi, Yanxia Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0025 PubMed DOI |
| 5. | First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression Author: Jia, Ru; Wang, Yan-Rong; Liu, Fang-Fang; Ma, Yue; Si, Hai-Yan; Han, Lu; Gou, Miao-Miao; Tan, Zhao-Li; Zhang, Nan; Deng, Guo-Chao; Fan, Meng-Jiao; Shi, Yue; Zhang, Yao-Yue; Jia, Yu-Shan; Xu, Jun-Nan; Su, Xiao-Xing; Han, Quan-Li; Wang, Zhi-Kuan; Dai, Guang-Hai Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0024 PubMed DOI |
| 6. | Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy Author: An, Mengchao; Yan, Jiayao; Liu, Baorui; Liu, Qin Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0023 PubMed DOI |
| 7. | The Roles of Protein S-Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential Author: Zheng, Haonan; Sun, Xiaoyu; Gao, Yang; Wang, Qinbiao; Wang, Jiaqi; Wei, Minjie; Tang, Yu; He, Miao Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0017 PubMed DOI |
| 8. | TOPK Suppresses the CD8+ T Cell Antitumor Immunity via Modulation of IRF5 Expression Author: Zang, Nianke; Gan, Jinfeng; Chen, Ye; Huang, Zheng; Xie, Chichu; Dang, Junlong; Huang, Changyuan; Yang, Linjie; Chen, Xuelian; Rong, Guangli; Sun, Jianbo; Shao, Yiming; Wang, Julie; Qi, Guangying; Liu, Yu; Zheng, Song Guo Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0021 PubMed DOI |
| 9. | Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial Author: Bao, Zhaoshi; Xue, Yake; Liu, Yanhui; Li, Shouwei; Wang, Liang; Qu, Yan; Mou, Yonggao; Yu, Rutong; Wu, Jinsong; Yao, Yu; Shu, Kai; Hu, Guangyuan; Cai, Linbo; Li, Wenbin; Qiu, Xiaoguang; Li, Yunqian; Zhang, Lei; Qi, Songtao; Ji, Ying; Ma, Chunxiao; Ma, Wenbin; Li, Gang; Tao, Rongjie; Sun, Chongran; Chen, Ligang; Lv, Sheng-Qing; Liang, Peng; Pan, Hao; Peter, Woo Yat Ming; Danny, Chan Tat Ming; Mao, Qing; Wei, Xinting; Jiang, Tao Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0019 PubMed DOI |
| 10. | Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma Author: Liao, Han; Zhao, Xuan; Chen, Liping; Liu, Qingyi; Li, Chenying; Li, Kai; Xi, Yiyi; Shen, Yanrong; Tan, Wen; Wu, Chen; Lin, Dongxin Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0014 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共259条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
